NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MH-17-018 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-199 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and participating Institutes within the National Institutes of Health (NIH) encourage small business SBIR grant applications to address different and complementary research needs for the development of appropriate pediatric drug formulations in different age groups. This FOA also encourages the development and testing of novel drug delivery systems in the pediatric population. The goal of this FOA is to complement and accelerate the development of appropriate pediatric drugs formulations and drug delivery systems.
Funding Opportunity PAR-17-200 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and participating Institutes within the National Institutes of Health (NIH) encourage small business grant applications to address different and complementary research needs for the development appropriate pediatric drug formulations in different age groups. This FOA also encourages the development and testing of novel drug delivery systems in the pediatric population. The goal of this FOA is to complement and accelerate the development of appropriate pediatric drugs formulations and drug delivery systems.
Funding Opportunity PAR-17-192 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. This FOA also encourages the development of novel drug delivery systems in the pediatric population. Investigators are encouraged to explore approaches and concepts new to the area of pediatric formulation development and testing and use newly developed techniques superior to the ones currently used in the field. Applications submitted under this mechanism should be exploratory and novel.
Funding Opportunity PAR-17-191 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. This FOA also encourages the development of novel drug delivery systems in the pediatric population. Investigators are encouraged to explore approaches and concepts new to the area of pediatric formulation development and testing and use newly developed techniques superior to the ones currently used in the field. This FOA supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding.
Funding Opportunity PAR-17-193 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. Development and testing of novel pediatric drug delivery systems is also part of this initiative.
Funding Opportunity PAR-17-233 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.
Notice NOT-RM-17-011 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-010 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-008 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HS-17-010 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to continue the work of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) program which AHRQ began in 1995. For the past 21 years, the CAHPS team -- CAHPS grantees, the CAHPS Survey User Network, and AHRQ CAHPS staff -- has advanced the science of patients' experience, particularly through the development of CAHPS surveys and related materials that allow consumers to assess their quality-related experiences with their health plans, providers, and health care facility settings. The CAHPS surveys are now broadly used by governmental agencies and organizations such as the Centers for Medicare and Medicaid Services (CMS), other health care purchasers, and the National Committee for Quality Assurance for a variety of different purposes such as value-based purchasing, public reporting, and accreditation. Specifically, this RFA solicits research to be performed within five broad areas: a) Advancing the science of consumer assessment of patient experience; b) Continued innovation to ensure relevance to health services delivery and survey best practices; c) Reporting patient experience data; d) Quality improvement (QI) studies; and e) Developing internal and external program communication strategies. Each of these areas is described in detail in Part 2. Full Text of the Announcement.
Funding Opportunity RFA-OD-17-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Notice NOT-OD-17-050 from the NIH Guide for Grants and Contracts
Notice NOT-FD-17-006 from the NIH Guide for Grants and Contracts
Notice NOT-HG-17-004 from the NIH Guide for Grants and Contracts
Notice NOT-TR-17-013 from the NIH Guide for Grants and Contracts
Notice NOT-TR-17-014 from the NIH Guide for Grants and Contracts
Notice NOT-AT-17-005 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-17-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on the advanced development and rigorous validation of new enabling technologies/tools/capabilities with a transformative potential for cancer research and clinical oncology.